GlassScriptPhysician profile
Daniel W Branch
NPI 1790105245
$11,800.33
in general payments reported to CMS, 2019-2025
36 companies · $4,127 in 2025
The $4,127 reported for 2025 was more than what 78% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,811 · 2020: $126 · 2021: $355 · 2022: $568 · 2023: $824 · 2024: $2,990 · 2025: $4,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,042 · Travel and Lodging: $3,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,042.49 |
| Travel and Lodging | $3,897.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $3,063.55 | 2019-2024 | Teligen, Conduit |
| Medtronic, INC. | $2,112.86 | 2021-2025 | Mazor X System, Stealthstation S8 Platform |
| Stryker Corporation | $1,314.92 | 2019-2021 | |
| Globus Medical, INC. | $1,037.98 | 2021-2025 | Excelsius Gps, Hedron, Ellipse |
| Zimmer Biomet Holdings, INC. | $621.23 | 2019-2025 | Htr-Pekk |
| Depuy Synthes Sales INC. | $452.88 | 2020-2024 | Teligen |
| Alexion Pharmaceuticals, INC. | $400.36 | 2022-2024 | Ultomiris, Soliris |
| Abbvie INC. | $394.43 | 2022-2025 | Botox, Ubrelvy, Duopa |
| Ucb, INC. | $345.03 | 2022-2025 | Rystiggo, Nayzilam, Zilbrysq |
| Biogen, INC. | $299.05 | 2023-2025 | Vumerity, Skyclarys, Tysabri |
| Lundbeck LLC | $190.98 | 2022-2025 | Vyepti |
| Celgene Corporation | $175.16 | 2023-2025 | Zeposia |
| Amneal Pharmaceuticals LLC | $158.22 | 2022-2025 | Rytary, Crexont |
| Highridge Medical LLC | $142.18 | 2024 | Mobi-C Plug & Fit US |
| Astrazeneca Pharmaceuticals LP | $137.31 | 2022-2024 | Andexxa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $110.99 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $101.55 | 2023-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Eisai INC. | $93.46 | 2023-2025 | |
| Genentech USA, INC. | $72.32 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Csl Behring | $62.90 | 2025 | Hizentra |
| Amgen INC. | $60.65 | 2021-2022 | |
| Tg Therapeutics, INC. | $55.18 | 2025 | |
| Sk Life Science, INC. | $50.53 | 2025 | |
| Argenx US, INC. | $46.85 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Si-Bone, INC. | $43.99 | 2020 | |
| Acadia Pharmaceuticals INC | $34.42 | 2025 | Nuplazid |
| Sanara Medtech INC. | $33.23 | 2022 | |
| Vanda Pharmaceuticals INC. | $27.01 | 2024 | Ponvory |
| Alnylam Pharmaceuticals INC. | $25.45 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.71 | 2023 | |
| Neurocrine Biosciences, INC. | $24.41 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $23.72 | 2024 | Exparel |
| Grt US Holding, INC. | $22.19 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.66 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.46 | 2022 | |
| Azurity Pharmaceuticals, INC. | $7.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Branch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.